Trial Profile
A Phase II Study Of Abraxane [paclitaxel] and Nexavar [sorafenib] in the First-Line Treatment of Locally Advanced or Metastatic Breast Cancer.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary) ; Paclitaxel
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 01 Dec 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 07 Mar 2008 New trial record.